Article may be outdated

This article is 7 days old. Some details may have changed since publication.

The Guardian·3 min read·medium

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

M
Maya Yang
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
✦AI Summary

The FDA is requiring manufacturers of GLP-1 weight loss drugs, such as Ozempic and Wegovy, to add warning labels regarding a rare eye condition called NAION. This follows a study suggesting a potential link between the medications and sudden vision loss.

Why it matters

This regulatory action highlights the ongoing safety monitoring of popular weight-loss drugs and the importance of patient awareness regarding potential side effects.

✦Dive DeeperCreate a free account to unlock

The FDA is requiring all GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy to carry the risk on warning labels. The FDA is requiring all GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy to carry the risk on warning labels. US news FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels

Prefer the Guardian on Google The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness .

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusiness
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in